A systematic review of the association between immunogenomic markers and cancer-related fatigue

Brain, Behavior, and Immunity

Volumn 26, Issue 6, 2012, Pages 830-848

  Saligan, L N ^a   Kim, H S ^a  

^a NATIONAL INSTITUTE OF NURSING RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD4 ANTIGEN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER FATIGUE; COLON CANCER; DISEASE ASSOCIATION; GENETIC MARKER; GENOMICS; HOMOZYGOTE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MONOCYTE; NATURAL KILLER CELL; NEUTROPHIL; PRIORITY JOURNAL; REVIEW; SYMPTOM; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; BREAST NEOPLASMS; C-REACTIVE PROTEIN; CD4-POSITIVE T-LYMPHOCYTES; CROSS-SECTIONAL STUDIES; CYTOKINES; FATIGUE; FEMALE; GENETIC MARKERS; GENOMICS; HUMANS; LONGITUDINAL STUDIES; NEOPLASMS; RISK FACTORS; SURVIVORS;

EID: 84863865198     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2012.05.004     Document Type: Review

References (63)

1. Ahlberg K., Ekman T., Gaston-Johansson F. Levels of fatigue compared to levels of cytokines and hemoglobin during pelvic radiotherapy: a pilot study. Biol. Res. Nurs. 2004, 5:203-210.
2. Alexander S., Minton O., Andrews P., Stone P. A comparison of the characteristics of disease-free cancer survivors with or without cancer-related fatigue syndrome. Eur. J. Cancer 2009, 45:384-392.
3. Aouizerat B.E., Dodd M., Lee K., West C., Paul S.M., Cooper B.A., et al. Preliminary evidence of a genetic association between tumor necrosis factor alpha and the severity of sleep disturbance and morning fatigue. Biol. Res. Nurs. 2009, 11:27-41.
4. Apte R.N., Dotan S., Elkabets M., White M.R., Reich E., Carmi Y., et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006, 25:387-408.
5. Banks W.A., Plotkin S.R., Kastin A.J. Permeability of the blood-brain barrier to soluble cytokine receptors. Neuroimmunomodulation 1995, 2:161-165.
6. Berger A.M., Abernethy A.P., Atkinson A., Barsevick A.M., Breitbart W.S., Cella D., et al. Cancer-related fatigue. J. Natl. Compr. Canc. Netw. 2010, 8:904-931.
7. Booker R., Olson K., Pilarski L.M., Noon J.P., Bahlis N.J. The relationships among physiologic variables, quality of life, and fatigue in patients with multiple myeloma. Oncol. Nurs. Forum 2009, 36:209-216.
8. Bower J.E., Ganz P.A., Aziz N., Fahey J.L. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom. Med. 2002, 64:604-611.
9. Bower J.E., Ganz P.A., Aziz N., Fahey J.L., Cole S.W. T-cell homeostasis in breast cancer survivors with persistent fatigue. J. Natl. Cancer Inst. 2003, 95:1165-1168.
10. Bower J.E., Ganz P.A., Aziz N., Olmstead R., Irwin M.R., Cole S.W. Inflammatory responses to psychological stress in fatigued breast cancer survivors: relationship to glucocorticoids. Brain Behav. Immun. 2007, 21:251-258.
11. Bower J.E., Ganz P.A., Tao M.L., Hu W., Belin T.R., Sepah S., et al. Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. Clin. Cancer Res. 2009, 15:5534-5540.
12. Bower J.E., Ganz P.A., Irwin M.R., Arevalo J.M., Cole S.W. Fatigue and gene expression in human leukocytes: increased NF-κB and decreased glucocorticoid signaling in breast cancer survivors with persistent fatigue. Brain Behav. Immune. 2011, 25:147-150.
13. Bower J.E., Ganz P.S., Irwin M.R., Kwan L., Breen E.C., Cole S.W. Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism?. J. Clin. Oncol. 2011, 29:3517-3522.
14. Cella, D., Davis, K., Breitbart, W., Curt, G., Fatigue Coalition, 2001. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J. Clin. Oncol. 19, 3385-3391.
15. Collado-Hidalgo A., Bower J.E., Ganz P.A., Cole S.W., Irwin M.R. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin. Cancer Res. 2006, 12:2759-2766.
16. Collado-Hidalgo A., Bower J.E., Ganz P.A., Irwin M.R., Cole S.W. Cytokine gene polymorphisms and fatigue in breast cancer survivors: early findings. Brain Behav. Immun. 2008, 22:1197-1200.
17. Curt G.A., Breitbart W., Cella D., Groopman J.E., Horning S.J., Itri L.M., et al. Impact of cancer-related fatigue on the lives of patients: new findings from the fatigue coalition. Oncologists 2000, 5:353-360.
18. Fernandez-de-las-Penas C., Fernandez-Lao C., Cantarero-Villanueva I., Ambite-Quesada S., Rivas-Martinez I., Del Moral-Avila R., et al. Catechol-O-methyltransferase genotype (Val158met) modulates cancer-related fatigue and pain sensitivity in breast cancer survivors. Breast Cancer Res. Treat. 2011, E-pub ahead of publication. 10.1007/s10549-011-1757-y.
19. Fieren M.W. The local inflammatory responses to infection of the peritoneal cavity in humans: their regulation by cytokines, macrophages, and other leukocytes. Mediators Inflamm. 2012, 2012:976241.
20. Fuchs D., Hausen A., Reibnegger G., Werner E.R., Dierich M.P., Wachter H. Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol. Today 1988, 9:150-155.
21. Fung A., Vizcaychipi M., Lloyd D., Wan Y., Ma D. Central nervous system inflammation in disease related conditions: mechanistic prospects. Brain Res. 2012, 1446:144-155.
22. Geinitz H., Zimmermann F.B., Stoll P., Thamm R., Kaffenberger W., Ansorg K., et al. Fatigue, serum cytokine levels, and blood cell counts during radiotherapy of patients with breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 2001, 51:691-698.
23. Inagaki M., Isono M., Okuyama T., Sugawara Y., Akechi T., Akizuki N., et al. Plasma interleukin-6 and fatigue in terminally ill cancer patients. J. Pain Symptom Manage. 2008, 35:153-161.
24. Kambur O., Männistö P.T. Catechol-O-methyltransferase and pain. Int. Rev. Neurobiol. 2010, 95:227-279.
25. Kaszas K., Keller J.M., Coddou C., Mishra S.K., Hoon M.A., Stojilkovic S., et al. Small molecular positive allosteric modulation of TRPV1 activation by vanilloids and acidic pH. J. Pharmacol. Exp. Ther. 2012, 340:152-160.
26. Keers R., Uher R. Gene-environment interaction in major depression and antidepressant treatment response. Curr. Psychiatry Rep. 2012, 14:129-137.
27. Konsman J.P., Vigues S., Mackerlova L., Bristow A., Blomqvist A. Rat brain vascular distribution of interleukin-1 type-1 receptor immunoreactivity: relationship to patterns of inducible cyclooxygenase expression by peripheral inflammatory stimuli. J. Comp. Neurol. 2004, 472:113-129.
28. Kwak S.M., Choi Y.S., Yoon H.M., Kim D.G., Song S.H., Lee Y.J., et al. The relationship between interleukin-6, tumor necrosis factor-{alpha}, and fatigue in terminally ill cancer patients. Palliat. Med. 2012, 26:275-282.
29. Landmark-Høyvik H., Reinertsen K.V., Loge J.H., Fosså S.D., Børresen-Dale A.L., Dumeaux V. Alterations of gene expression in blood cells associated with chronic fatigue in breast cancer survivors. Pharmacogenomics J. 2009, 9:333-340.
30. Laugsand E.A., Fladvad T., Skorpen F., Maltoni M., Kaasa S., Fayers P., et al. Clinical and genetic factors associated with nausea and vomiting in cancer patients receiving opioids. Eur. J. Cancer 2011, 47:1682-1691.
31. Ma Y., Kepp O., Ghiringhelli F., Apetoh L., Aymeric L., Locher C., et al. Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin. Immunol. 2010, 22:113-124.
32. Meyers C.A., Albitar M., Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2005, 104:788-793.
33. Miakowski, C.A., 2002. Assessment and management of cancer-related fatigue. In: Berger, A.M. (Ed.), Principles and Practice of Palliative Care and Supportive Oncology. Lippincott William & Wilkins, Philadelphia, PA, p. 143.
34. Miaskowski C., Dodd M., Lee K., West C., Paul S.M., Cooper B.A., et al. Preliminary evidence of an association between a functional interleukin-6 polymorphism and fatigue and sleep disturbance in oncology patients and their family caregivers. J. Pain Symptom Manage. 2010, 40:531-544.
35. Miller L.J., Kurtzman S.H., Anderson K., Wang Y., Stankus M., Renna M., et al. Interleukin-1 family expression in human breast cancer: interleukin-1 receptor antagonist. Cancer Invest. 2000, 18:293-302.
36. Mills P.J., Parker B., Dimsdale J.E., Sadler G.R., Ancoli-Israel S. The relationship between fatigue and quality of life and inflammation during anthracycline-based chemotherapy in breast cancer. Biol. Psychol. 2005, 69:85-96.
37. Minton O., Stone P. A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). Ann. Oncol. 2009, 20:17-25.
38. Minton O., Strasser F., Radbruch L., Stone P. Identification of factors associated with fatigue in advanced cancer: a subset analysis of the European palliative care research collaborative computerized symptom assessment data set. J. Pain Symptom Manage. 2012, 43:226-235.
39. O'Connor P.J. Evaluation of four highly cited energy and fatigue mood measures. J. Psychosom. Res. 2004, 57:435-441.
40. Okuyama T., Akechi T., Kugaya A., Okamura H., Shima Y., Maruguchi M., et al. Development and validation of the cancer fatigue scale: a brief, three-dimensional, self-rating scale for assessment of fatigue in cancer patients. J. Pain Symptom Manage. 2000, 19:5-14.
41. Olson K., Tom B., Hewitt J., Whittingham J., Buchanan L., Ganton G. Evolving routines: preventing fatigue associated with lung and colorectal cancer. Qual. Health Res. 2002, 12:655-670.
42. Orre I.J., Reinertsen K.V., Aukrust P., Dahl A.A., Fosså S.D., Ueland T., et al. Higher levels of fatigue are associated with higher CRP levels in disease-free breast cancer survivors. J. Psychosom. Res. 2011, 71:136-141.
43. Orre I.J., Murison R., Dahl A.A., Ueland T., Aukrust P., Fosså S.D. Levels of circulating interleukin-1 receptor antagonist and C-reactive protein in long-term survivors of testicular cancer with chronic cancer-related fatigue. Brain Behav. Immun. 2009, 23:868-874.
44. Paddison J.S., Temel J.S., Fricchione G.L., Pirl W.F. Using the differential from complete blood counts as a biomarker of fatigue in advanced non-small-cell lung cancer: an exploratory analysis. Palliat. Support Care 2009, 7:213-217.
45. Panju A.H., Danesh A., Minden M.D., Kelvin D.J., Alibhai S.M. Associations between quality of life, fatigue, and cytokine levels in patients aged 50+ with acute myeloid leukemia. Support Care Cancer 2009, 17:539-546.
46. Pantschenko A.G., Pushkar I., Anderson K.H., Wang Y., Miller L.J., Kurtzman L.J., et al. The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumour progression. Int. J. Oncol. 2003, 23:269-284.
47. Rausch S.M., Clark M.M., Patten C., Liu H., Felten S., Li Y., et al. Relationship between cytokine gene single nucleotide polymorphisms and symptom burden and quality of life in lung cancer survivors. Cancer 2010, 116:4103-4113.
48. Reinertsen K.V., Grenaker Alnæs G.I., Landmark-Høyvik H., Loge J.H., Wist E., Kristensen V.N., et al. Fatigued breast cancer survivors and gene polymorphisms in the inflammatory pathway. Brain Behav. Immun. 2011, 25:1376-1383.
49. Ruffell B., DeNardo D.G., Affara N.I., Coussens L.M. Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev. 2010, 21:3-10.
50. Scheede-Bergdahl C., Watt H.L., Trutschnigg B., Kilgour R.D., Haggarty A., Lucar E., et al. Is IL-6 the best pro-inflammatory biomarker of clinical outcomes of cancer cachexia?. Clin. Nutr. 2012, 31:85-88. E-pub ahead of publication.
51. Schenk S., Saberi M., Olefsky J.M. Insulin sensitivity: modulation by nutrients and inflammation. J. Clin. Investig. 2008, 118:2992-3002.
52. Schroecksnadel K., Fiegl M., Prassl K., Winkler C., Denz H.A., Fuchs D. Diminished quality of life in patients with cancer correlates with tryptophan degradation. J. Cancer Res. Clin. Oncol. 2007, 133:477-485.
53. Scott H.R., McMillan D.C., Forrest L.M., Brown D.J., McArdle C.S., Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br. J. Cancer 2002, 87:264-267.
54. Strey A., Janning A., Barth H., Gerke V. Endothelial Rho signaling is required for monocyte transendothelial migration. FEBS Lett. 2002, 517:261-266.
55. Vallance K., Liu W., Mandrell B.N., Panetta J.C., Gattuso J.S., Hockenberry M., et al. Mechanisms of dexamethasone-induced disturbed sleep and fatigue in paediatric patients receiving treatment for ALL. Eur. J. Cancer 2010, 46:1848-1855.
56. Von Ah D.M., Kang D.H., Carpenter J.S. Predictors of cancer-related fatigue in women with breast cancer before, during, and after adjuvant therapy. Cancer Nurs. 2008, 31:134-144.
57. Voronov E., Reich E., Dotan S., Dransh P., Cohen I., Huszar M., et al. Effects of IL-1 molecules on growth patterns of 3-MCA-induced cell lines: an interplay between immunogenicity and invasive potential. J. Immunotoxicol. 2010, 7:27-38.
58. Weis J. Cancer-related fatigue: prevalence, assessment, and treatment strategies. Expert. Rev. Pharmacoecon Outcomes Res. 2011, 11:441-446.
59. Whitehead L. The measurement of fatigue in chronic illness: a systematic review of unidimensional and multidimensional fatigue measures. J. Pain Symptom Manage. 2009, 37:107-128.
60. Whiteside T.L. Immune responses to malignancies. J. Allergy Clin. Immunol. 2010, 125:S272-S283.
61. Whiteside T.L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008, 27:5904-5912.
62. Whiteside T.L. The role of immune cells in the tumor microenvironment. Cancer Treat Res. 2006, 130:103-124.
63. Wratten C., Kilmurray J., Nash S., Seldon M., Hamilton C.S., O'Brien P.C., et al. Fatigue during breast radiotherapy and its relationship to biological factors. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59:160-167.